We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

55 hedge funds and large institutions have $168M invested in NKGen Biotech, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $155M → $168M (+$12.7M)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

7% less funds holding

Funds holding: 59 → 55 (-4)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

Holders
55
Holders Change
-4
Holders Change %
-6.78%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
8
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$8.14M
2
PC
Periscope Capital
Ontario, Canada
+$4.6M
3
UOC
UBS O'Connor
Illinois
+$3.23M
4
KL
KIM LLC
Kansas
+$3.03M
5
KIM
Karpus Investment Management
New York
+$2.95M

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$5.87M
2
CAC
Cowen and Company
New York
-$3.62M
3
TCA
Taconic Capital Advisors
New York
-$3.48M
4
JP Morgan Chase
JP Morgan Chase
New York
-$2.37M
5
EC
Elequin Capital
New York
-$2.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
RL
26
RPO LLC
Connecticut
$2.4M +$474K +47,001 +25%
FBCM
27
Fort Baker Capital Management
California
$2.04M – – –
JP Morgan Chase
28
JP Morgan Chase
New York
$2.03M -$2.37M -234,433 -54%
FTCM
29
First Trust Capital Management
Illinois
$2.03M +$2.02M +200,201 New
AIMCA
30
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$2.03M – – –
MTCM
31
Mint Tower Capital Management
Netherlands
$2.03M – – –
SCM
32
Shaolin Capital Management
Florida
$2.03M – – –
Millennium Management
33
Millennium Management
New York
$1.55M – – –
ACM
34
Atalaya Capital Management
New York
$1.52M – – –
CH
35
CVI Holdings
Delaware
$1.52M +$1.51M +150,000 New
BI
36
Bulldog Investors
New Jersey
$1.01M – – –
OCM
37
Oaktree Capital Management
California
$1.01M – – –
SC
38
Sculptor Capital
New York
$1.01M – – –
GCIA
39
Gabelli & Co Investment Advisers
New York
$873K – – –
AA
40
AQR Arbitrage
Connecticut
$709K – – –
DAM
41
Deltec Asset Management
New York
$699K +$696K +69,000 New
Walleye Capital
42
Walleye Capital
New York
$647K – – –
SIA
43
Schechter Investment Advisors
Michigan
$571K – – –
PI
44
PEAK6 Investments
Illinois
$559K – – –
MC
45
Meteora Capital
Florida
$553K +$351K +34,746 +175%
DCM
46
Difesa Capital Management
New York
$538K – – –
COPPSERS
47
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$507K – – –
Walleye Trading
48
Walleye Trading
New York
$365K – – –
BFM
49
Boothbay Fund Management
New York
$324K – – –
SSA
50
Schonfeld Strategic Advisors
New York
$236K -$71.6K -7,100 -23%
1
2
3

NKGN Hedge Fund Activity: Q1 2023 in Review

55 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q1 2023, worth a combined $168M — up 8.2% from $155M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of NKGN and 7 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 8 added.

The largest buyer was Aristeia Capital, opening a new position worth an estimated $8.14M. The largest seller was Marshall Wace, exiting entirely with an estimated $5.87M sold.

  • 55 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q1 2023, down from 59 in Q4 2022.
  • Funds reported $168M of NKGen Biotech, Inc. Common Stock stock for Q1 2023, up 8.2% quarter-over-quarter.
  • 7 funds opened new NKGen Biotech, Inc. Common Stock positions in Q1 2023 and 10 closed out, a net change of -3 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q1 2023 was Aristeia Capital, an estimated $8.14M added.
  • The largest NKGen Biotech, Inc. Common Stock seller in Q1 2023 was Marshall Wace, an estimated $5.87M sold.

Based on aggregated 13F filings for Q1 2023.